Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
62 GF Score
Price ¥8.40
GF Value ¥4.96
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Henan Taloph Pharmaceutical Stock Co is: High Risk: High uncertainty with risk-return tradeoff.

Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Henan Taloph Pharmaceutical Stock Co Risk Assessment Related Terms

SHSE:600222 vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Henan Taloph Pharmaceutical Stock Co Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Risk Assessment falls into.


SHSE:600222
62GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥8.40 is trading 69.4% above its estimated GF Value™ of ¥4.96. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • Risk Assessment:
  • GF Value™: ¥4.96 vs. price of ¥8.40 (69.4% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
62GF Score

Get the complete analysis for SHSE:600222

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.40
Price
¥4.96
GF Value